Showing 3541-3550 of 4164 results for "".
- Luxa Biotechnology Presents Data from First-in-Human Retinal Pigment Epithelium Cell Therapy for Dry AMDhttps://modernod.com/news/luxa-biotechnology-presents-data-from-first-in-human-retinal-pigment-epithelium-cell-therapy-for-dry-amd/2482693/Luxa Biotechnology announced clinical data from its phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (AMD). The data were presented at the 77th Annual Wills Eye Conference in Phila
- CASExGLOBAL Launches First AI-Powered Site Management Organizationhttps://modernod.com/news/casexglobal-lauches-first-ai-powered-site-management-organization/2482484/The Centers for Advanced Surgical Exploration (CASExGLOBAL) announced a new partnership with Clinical AI and iOR Partners to introduce what it is calling the first AI-powered site management organization (SMO) and bring clinical trials to ophthalmic office-based surgery (OBS) centers. i
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- Emily Chew, MD, Named NIH Distinguished Investigatorhttps://modernod.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/Emily, Chew, MD, has been promoted to the title of NIH Distinguished Investigator for her work as a care provider and clinical trialist. Dr. Chew directs National Eye Institute's Division of Epidemiology and Clinical Applications (DECA). An ophthalmologist, she specializes in c
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev
- Sydnexis Appoints Nick Ruth Chief as Commercial Officerhttps://modernod.com/news/sydnexis-appoints-nick-ruth-chief-as-commercial-officer/2481799/Sydnexis has announced the appointment of industry veteran Nick Ruth, MBA, as its Chief Commercial Officer (COO). Mr. Ruth will lead Sydnexis’ commercial strategy and transition from a clinical based organization to both a clinical and commercial based organization. With
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s